Revolo Biotherapeutics Reports the Results for IRL201104 in P-IIa Trial for the Treatment of Seasonal Allergic Rhinitis
Shots:
- The P-IIa clinical trial evaluates the safety, tolerability & immunologic mechanism of IRL201104 (8mg) vs PBO in patients (n=63) with moderate to severe seasonal allergic rhinitis. Post 8hrs. of drug administration, patients were evaluated for mean diameter of the intradermal challenge LPR & other immune system responses
- The results depicted a rapid reduction in the allergic inflammation vs PBO along with a sustained increase in activated IL-10+ Tregs & IL-10+ Bregs. Moreover, the avg. wheal diameter surface area reductions were 23% vs 40%
- The company has recently advanced, IRL201104 into 2 P-IIa clinical trials in patients with eosinophilic esophagitis & allergen sensitivity
Ref: Globenewswire | Image: Revolo Biotherapeutics
Related News:- Glenmark’s Ryaltris Nasal Spray Receives the US FDA’s Approval for the Treatment of Seasonal Allergic Rhinitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
